|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS, SUCH AS ASPIRIN, MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS, SUCH AS ASPIRIN, MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS, SUCH AS ASPIRIN, MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS, SUCH AS ASPIRIN, MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS, SUCH AS ASPIRIN, MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS, SUCH AS ASPIRIN, MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS, SUCH AS ASPIRIN, MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS, SUCH AS ASPIRIN, MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION WITH INTRAVENOUS DEXTRAN BEFORE CORONARY INTERVENTION, OR INTENT TO USE IT DURING AN INTERVENTION IS CONTRAINDICATED.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
INCREASED CHANCES OF BLEEDING
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS, SUCH AS ASPIRIN, MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS, SUCH AS ASPIRIN, MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION WITH OTHER ANTICOAGULANT AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS, SUCH AS ASPIRIN, MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|